Blog
27 Articles
![Kim Reiss Binder](https://letswinpc.org/wp-content/uploads/2022/10/Kim-Reiss-Binder.jpg)
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
![Dr. Aimee Lucas](https://letswinpc.org/wp-content/uploads/2018/10/Aimee-lucas-v2.jpg)
Which Is the Best Screening Method for Pancreatic Cancer?
Dr. Aimee Lucas outlines the pros and cons of various screening methods that can be used for pancreatic cancer, and who should be using them.
![Illustration of a protein that includes the BRCA2 mutation. The illustration includes spirals in brown, strands in purple, blue directional arrows, and green, yellow, red, and blue circles.](https://letswinpc.org/wp-content/uploads/2022/09/ct2017jun27.jpg)
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
![A paper model of DNA to illustrate genetic testing](https://letswinpc.org/wp-content/uploads/2022/09/ct2017may9.jpg)
Treating BRCA-Negative Pancreatic Cancer Patients with a Family Cancer History Similar to BRCA Carriers
A clinical trial looks at the effectiveness of a PARP inhibitor in BRCA-negative pancreatic cancer patients with a family history BRCA-type cancers.
![Pancreas cross section embedded in paraffin wax, stained blue and purple, 100x magnification.](https://letswinpc.org/wp-content/uploads/2022/09/ct2017jan16.jpg)
Comparing a Standard Chemotherapy With and Without a PARP Inhibitor
A clinical trial compares standard chemotherapy with and without the addition of a PARP inihibitor, for patients whose pancreatic cancer is spreading again.
![Illustration of the twisting spirals of two DNA double helices in royal blue and purple on a turquoise colored background](https://letswinpc.org/wp-content/uploads/2022/09/ct2016oct18.jpg)
A New Drug Combination to Control Advanced Pancreatic Cancer
A clinical trial for pancreatic cancer patients with the BRCA mutation tests the effectiveness of standard treatment plus a PARP inhibitor.
![Microscope image of four pancreatic cells with pinkish edges and green centers, against a dark background](https://letswinpc.org/wp-content/uploads/2022/09/ct2016oct10.jpg)
A Novel Combination to Slow Pancreas Tumors that Cannot Be Surgically Removed
Can a combination of standard drugs, a PARP inhibitor, and intensity modulated radiation therapy to slow pancreatic tumor growth?
![Microscopy image of a tumor section (obtained from a mouse tumor model) shows the blue-stained nanoparticles selectively accumulating in the peripheral tumor area and then penetrating into tumor cells](https://letswinpc.org/wp-content/uploads/2022/09/ct2016aug18.gif)
Exploring the Effectiveness of an Experimental Class of Drug
Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?
![test tubes with red and yellow liquids](https://letswinpc.org/wp-content/uploads/2016/07/ct2016jul26-yellow-red.jpg)
Maintenance Chemotherapy Trial for Pancreatic Cancer Patients with the BRCA Mutation
A clinical trial for patients with BRCA mutations uses a PARP inhibitor as part of the maintenance chemotherapy experimental treatment.